Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Acrivon Therapeutics NASDAQ:ACRV ) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. View our latest analysis for Acrivon Therapeutics How Long Is Acrivon Therapeutics' Cash Runway? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Acrivon Therapeutics last reported its December 2023 balance sheet in Marc
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) was downgraded by analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at BMO Capital Markets from $18.00 to $25.00. They now have an "outperform" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at JMP Securities from $14.00 to $17.00. They now have a "market outperform" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at Piper Sandler from $26.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
ACRV
Earnings
- 8/11/23 - Beat
ACRV
Sec Filings
- 4/30/24 - Form EFFECT
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- ACRV's page on the SEC website